Perinatal Institute and James M, Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, USA.
BMC Health Serv Res. 2011 Jan 31;11:22. doi: 10.1186/1472-6963-11-22.
Proposed neonatal quality measures have included structural measures such as average daily census, and outcome measures such as mortality and rates of complications of prematurity. However, process measures have remained largely unexamined. The objective of this research was to examine variation in surfactant use as a possible process measure of neonatal quality.
We obtained data on infants 30 to 34 weeks gestation admitted with respiratory distress syndrome (RDS) within 48 hours of birth to 16 hospitals participating in the Pediatric Health Information Systems database from 2001-2006. Models were developed to describe hospital variation in surfactant use and identify patient and hospital predictors of use. Another cohort of all infants admitted within 24 hours of birth was used to obtain adjusted neonatal intensive care unit (NICU) mortality rates. To assess the construct validity of surfactant use as a quality metric, adjusted hospital rates of mortality and surfactant use were compared using Kendall's tau.
Of 3,633 infants, 46% received surfactant. For individual hospitals, the adjusted odds of surfactant use varied from 2.2 times greater to 5.9 times less than the hospital with the median adjusted odds of surfactant use. Increased annual admissions of extremely low birth weight infants to the NICU were associated with greater surfactant use (OR 1.80, 95% CI 1.02-3.19). The correlation between adjusted hospital rates of surfactant use and in-hospital mortality was 0.37 (Kendall's tau p = 0.051).
Though results were encouraging, efforts to examine surfactant use in infants with RDS as a process measure reflecting quality of care revealed significant challenges. Difficulties related to adequate measurement including defining RDS using administrative data, accounting for care received prior to transfer, and adjusting for severity of illness will need to be addressed to improve the utility of this measure.
已提出的新生儿质量衡量标准包括结构指标,如平均每日统计,以及结果指标,如死亡率和早产儿并发症发生率。然而,过程指标在很大程度上仍未得到检验。本研究的目的是检验表面活性剂的使用情况,作为新生儿质量的一种可能的过程衡量标准。
我们从 2001 年至 2006 年,从参与儿科健康信息系统数据库的 16 家医院中,获得了胎龄为 30 至 34 周、出生后 48 小时内因呼吸窘迫综合征(RDS)入院的婴儿的数据。建立模型来描述医院在使用表面活性剂方面的差异,并确定使用表面活性剂的患者和医院预测因素。还使用所有出生后 24 小时内入院的婴儿的另一队列来获得调整后的新生儿重症监护病房(NICU)死亡率。为了评估使用表面活性剂作为质量指标的结构有效性,使用 Kendall's tau 比较了调整后的医院死亡率和表面活性剂使用率。
在 3633 名婴儿中,有 46%接受了表面活性剂治疗。对于个别医院,调整后的使用表面活性剂的几率是中位数调整后使用表面活性剂几率的医院的 2.2 倍至 5.9 倍不等。NICU 中极低出生体重儿的年入院人数增加与表面活性剂使用增加相关(OR 1.80,95%CI 1.02-3.19)。调整后的医院表面活性剂使用率和院内死亡率之间的相关性为 0.37(Kendall's tau p=0.051)。
尽管结果令人鼓舞,但在患有 RDS 的婴儿中使用表面活性剂作为反映护理质量的过程指标的尝试,揭示了一些重大挑战。与充分测量相关的困难,包括使用行政数据定义 RDS、核算转院前接受的治疗以及调整疾病严重程度,都需要加以解决,以提高这一衡量标准的效用。